128 related articles for article (PubMed ID: 17291350)
1. Improved generation of anti-tumor immunity by antigen dose limitation.
Shofner JD; Vasquez JG; Berger CL; Edelson RL
J Immune Based Ther Vaccines; 2007 Feb; 5():2. PubMed ID: 17291350
[TBL] [Abstract][Full Text] [Related]
2. Rapid construction of a dendritic cell vaccine through physical perturbation and apoptotic malignant T cell loading.
Salskov-Iversen M; Berger CL; Edelson RL
J Immune Based Ther Vaccines; 2005 Jul; 3():4. PubMed ID: 16029505
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells.
Berger CL; Tigelaar R; Cohen J; Mariwalla K; Trinh J; Wang N; Edelson RL
Blood; 2005 Feb; 105(4):1640-7. PubMed ID: 15514008
[TBL] [Abstract][Full Text] [Related]
4. The life cycle of cutaneous T cell lymphoma reveals opportunities for targeted drug therapy.
Berger CL; Edelson R
Curr Cancer Drug Targets; 2004 Nov; 4(7):609-19. PubMed ID: 15578918
[TBL] [Abstract][Full Text] [Related]
5. Interaction of cutaneous lymphoma cells with reactive T cells and dendritic cells: implications for dendritic cell-based immunotherapy.
Thumann P; Lüftl M; Moc I; Bagot M; Bensussan A; Schuler G; Jenne L
Br J Dermatol; 2003 Dec; 149(6):1128-42. PubMed ID: 14674889
[TBL] [Abstract][Full Text] [Related]
6. Development of immunogenic tumor-loaded dendritic cells through physical perturbation and apoptotic cell loading.
Shen X; Berger CL; Tigelaar R; Edelson RL
Immunol Invest; 2008; 37(8):798-821. PubMed ID: 18991097
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
Edelson RL
Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
[TBL] [Abstract][Full Text] [Related]
8. The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells.
Berger CL; Hanlon D; Kanada D; Dhodapkar M; Lombillo V; Wang N; Christensen I; Howe G; Crouch J; El-Fishawy P; Edelson R
Blood; 2002 Apr; 99(8):2929-39. PubMed ID: 11929784
[TBL] [Abstract][Full Text] [Related]
9. Tumor-specific peptides in cutaneous T-cell lymphoma: association with class I major histocompatibility complex and possible derivation from the clonotypic T-cell receptor.
Berger CL; Longley BJ; Imaeda S; Christensen I; Heald P; Edelson RL
Int J Cancer; 1998 May; 76(3):304-11. PubMed ID: 9579563
[TBL] [Abstract][Full Text] [Related]
10. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody.
Ha D; Tanaka A; Kibayashi T; Tanemura A; Sugiyama D; Wing JB; Lim EL; Teng KWW; Adeegbe D; Newell EW; Katayama I; Nishikawa H; Sakaguchi S
Proc Natl Acad Sci U S A; 2019 Jan; 116(2):609-618. PubMed ID: 30587582
[TBL] [Abstract][Full Text] [Related]
11. Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells.
Kurokawa T; Oelke M; Mackensen A
Int J Cancer; 2001 Mar; 91(6):749-56. PubMed ID: 11275975
[TBL] [Abstract][Full Text] [Related]
12. Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile.
Querfeld C; Leung S; Myskowski PL; Curran SA; Goldman DA; Heller G; Wu X; Kil SH; Sharma S; Finn KJ; Horwitz S; Moskowitz A; Mehrara B; Rosen ST; Halpern AC; Young JW
Cancer Immunol Res; 2018 Aug; 6(8):900-909. PubMed ID: 29895574
[TBL] [Abstract][Full Text] [Related]
13. Enhanced suppression of polyclonal CD8
Mu C; Zhang X; Wang L; Xu A; Ahmed KA; Pang X; Chibbar R; Freywald A; Huang J; Zhu Y; Xiang J
J Leukoc Biol; 2017 May; 101(5):1221-1231. PubMed ID: 28096300
[TBL] [Abstract][Full Text] [Related]
14. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755
[TBL] [Abstract][Full Text] [Related]
15. Possible therapeutic applicability of galectin-9 in cutaneous T-cell lymphoma.
Nakajima R; Miyagaki T; Kamijo H; Oka T; Shishido-Takahashi N; Suga H; Sugaya M; Sato S
J Dermatol Sci; 2019 Dec; 96(3):134-142. PubMed ID: 31787505
[TBL] [Abstract][Full Text] [Related]
16. Hepatoma cells inhibit the differentiation and maturation of dendritic cells and increase the production of regulatory T cells.
Li L; Li SP; Min J; Zheng L
Immunol Lett; 2007 Nov; 114(1):38-45. PubMed ID: 17945351
[TBL] [Abstract][Full Text] [Related]
17. DC-induced CD8(+) T-cell response is inhibited by MHC class II-dependent DX5(+)CD4(+) Treg.
Han WG; Schuurhuis DH; Fu N; Camps M; van Duivenvoorde LM; Louis-Plence P; Franken KL; Huizinga TW; Melief CJ; Toes RE; Ossendorp F
Eur J Immunol; 2009 Jul; 39(7):1765-73. PubMed ID: 19544486
[TBL] [Abstract][Full Text] [Related]
18. Induction of anti-tumor CD8 T cell responses by experimental ECP-induced human dendritic antigen presenting cells.
Kibbi N; Sobolev O; Girardi M; Edelson RL
Transfus Apher Sci; 2016 Aug; 55(1):146-52. PubMed ID: 27317354
[TBL] [Abstract][Full Text] [Related]
19. Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis.
Nevala H; Karenko L; Vakeva L; Ranki A
Br J Dermatol; 2001 Dec; 145(6):928-37. PubMed ID: 11899146
[TBL] [Abstract][Full Text] [Related]
20. Antitumour activity mediated by CD4+ cytotoxic T lymphocytes against MHC class II-negative mouse hepatocellular carcinoma induced by dendritic cell vaccine and interleukin-12.
Homma S; Komita H; Sagawa Y; Ohno T; Toda G
Immunology; 2005 Aug; 115(4):451-61. PubMed ID: 16011514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
